Small cell lung cancer (SCLC) is one of the most aggressive types of lung cancer, with a 5-year survival rate of only 5%. People often respond well to chemotherapy initially, but the effects are usually short-lived. Most patients experience a relapse, followed by rapid disease progression. Because of this pattern, understanding the biology behind SCLC is important to prolong treatment efficacy, prevent recurrence, and improve long-term outcomes.
A research team led by Professor Silvia von Karstedt (Translational Genomics, CECAD Aging Research Cluster of Excellence, Cologne Center for Molecular Medicine — CMMC) has identified a previously unknown process that may explain why this cancer behaves so aggressively. Their findings are: nature communicationscomes from a study titled “Caspase-8 deficiency induces neural progenitor-like reprogramming and progression of small cell lung cancer.”
Cancer cells with neuron-like characteristics
Unlike many other epithelial cancers, SCLC shares characteristics with nerve cells. One important feature is the absence of caspase-8, a protein that plays an important role in programmed non-inflammatory cell death (apoptosis). This process helps the body remove damaged or abnormal cells and is essential for maintaining healthy tissue.
Inflammatory cell death and immunosuppression
To better mimic how SCLC develops in humans, researchers created a genetically engineered mouse model lacking caspase-8. Using this model, they uncovered a chain reaction caused by the absence of this protein. “The absence of caspase-8 triggers a type of inflammatory cell death called necroptosis, creating a hostile inflammatory environment even before a tumor is fully formed,” von Karlstedt explains. “We were also intrigued by the finding that pretumor necrosis may actually promote cancer by modulating the immune system,” she continued.
This inflammatory environment weakens the body’s natural defenses by suppressing anti-cancer immune responses, making it difficult for immune cells to attack cancer threats. This results in more favorable conditions for tumor growth and metastasis. Researchers also found that inflammation pushes cancer cells into a more immature, neuron-like state, which increases their ability to metastasize and is associated with recurrence.
Implications for future treatment and early detection
It is still unclear whether this type of preneoplastic inflammation also occurs in human patients. However, this study highlights an important mechanism that may drive both the aggressiveness of SCLC and its tendency to relapse after treatment. These insights could help guide the development of more effective treatments and improve early detection strategies.
This study was supported by the German Research Foundation within the Cooperative Research Center (CRC) 1399 “Mechanisms of drug sensitivity and resistance in small cell lung cancer”.
